This study is looking at how a medication called Guanfacine Extended Release (6mg/day ER) might help people with alcohol use disorder. Researchers want to see if Guanfacine can reduce drinking, especially when people are feeling stressed or stimulated. You could join if you are between 21 and 70 years old, can read and write English, and meet criteria for alcohol use disorder (drinking more than 14 drinks per week for men, or 7 drinks per week for women, with frequent heavy drinking days). The study aims to see if Guanfacine helps reduce the amount of alcohol consumed during specific lab sessions and decreases heavy drinking days over a 6-week treatment period. The current status of this study is unclear.

Study design

This is a double-blind, placebo-controlled study, meaning neither you nor the study team will know if you're receiving Guanfacine or a placebo (an inactive substance). It plans to include 160 participants.

What's involved

You would have an intake session and physical exam. If eligible, you'd take medication for 3 weeks to reach a steady level, then participate in three lab sessions, followed by a 6-week treatment phase with weekly appointments.

Compensation

Not stated in the trial record.

Follow-up

After the 6-week treatment, medication will be tapered for 5 days, and you will have follow-up evaluations 1 and 3 months later.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.